Pharmaceutical companies' policies on access to trial data, results, and methods: Audit study

BMJ (Online)

Volumn 358, Issue , 2017, Pages

  Goldacre, Ben ^a   Lane, Síle ^b   Mahtani, Kamal R ^a   Heneghan, Carl ^a   Onakpoya, Igho ^a   Bushfield, Ian ^b   Smeeth, Liam ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Sense About Science USA   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; CLINICAL AUDIT; DRUG INDUSTRY; HUMAN; INFORMATION DISSEMINATION; INTERPERSONAL COMMUNICATION; MEDICAL ETHICS; MEDICAL LITERATURE; OFF LABEL DRUG USE; PHASE 4 CLINICAL TRIAL (TOPIC); POLICY; PRIORITY JOURNAL; UNLICENSED DRUG USE; CLINICAL TRIAL (TOPIC); DRUG CONTROL; LEGISLATION AND JURISPRUDENCE;

CLINICAL AUDIT; CLINICAL TRIALS AS TOPIC; DISCLOSURE; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; HUMANS;

EID: 85026346641     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j3334     Document Type: Article

References (47)

1. Schmucker C, Schell LK, Portalupi SOPEN consortium. Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries. PLoS One 2014;9:e114023. doi:10. 1371/journal. pone. 0114023
2. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med 2006;99:337-41. doi:10. 1258/jrsm. 99. 7. 337
3. Goldacre B. Are clinical trial data shared sufficiently today? No. BMJ 2013;347:f1880. doi:10. 1136/bmj. f1880
4. Kmietowicz Z. GSK backs campaign for disclosure of trial data. BMJ 2013;346:f819. doi:10. 1136/bmj. f819
5. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med 2013;369:475-8. doi:10. 1056/NEJMsr1302541
6. Bodoni S. AbbVie, InterMune Sue to Block Clinical-Trial Data Release. Bloomberg. 2013. http://www. bloomberg. com/news/2013-03-11/ abbvie-sues-eu-regulator-to-block-clinical-trial-data-release. html
7. Benjamin A. Audit: how to do it in practice. BMJ 2008;336:1241-5. doi:10. 1136/bmj. 39527. 628322. AD
8. Goldacre B. How to get all trials reported: audit, better data, and individual accountability. PLoS Med 2015;12:e1001821. doi:10. 1371/journal. pmed. 1001821
9. Ali MK, Narayan KM. The new Access to Medicine Index. Lancet 2008;372:891. doi:10. 1016/S0140-6736(08)61396-3
10. Tompson AC, Petit-Zeman S, Goldacre B, Heneghan CJ. Getting our house in order: an audit of the registration and publication of clinical trials supported by the National Institute for Health Research Oxford Biomedical Research Centre and the Musculoskeletal Biomedical Research Unit. BMJ Open 2016;6:e009285. doi:10. 1136/bmjopen-2015-009285
11. Patients endangered as law is ignored [Internet]. STAT. 2015 [cited 2016 Aug 10]. Available from: https://www. statnews. com/2015/ 12/13/clinical-trials-investigation/
12. Chen R, Desai NR, Ross JS. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ 2016;352:i637. doi:10. 1136/bmj. i637
13. Miller JE, Korn D, Ross JS. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. BMJ Open 2015;5:e009758. doi:10. 1136/bmjopen-2015-009758
14. Begum R, Kolstoe S. Can UK NHS research ethics committees effectively monitor publication and outcome reporting bias?BMC Med Ethics 2015;16:51. doi:10. 1186/s12910-015-0042-8
15. Laine C, De Angelis C, Delamothe T. Clinical trial registration: looking back and moving ahead. Ann Intern Med 2007;147:275-7. doi:10. 7326/0003-4819-147-4-200708210-00166
16. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials. gov results database-update and key issues. N Engl J Med 2011;364:852-60. doi:10. 1056/NEJMsa1012065
17. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 2009;302:977-84. doi:10. 1001/jama. 2009. 1242
18. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303:2058-64. doi:10. 1001/jama. 2010. 651
19. Turner L, Shamseer L, Altman DG. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev 2012;11:MR000030.
20. Hartung DM, Zarin DA, Guise J-M, McDonagh M, Paynter R, Helfand M. Reporting discrepancies between the ClinicalTrials. gov results database and peer-reviewed publications. Ann Intern Med 2014;160:477-83. doi:10. 7326/M13-0480
21. Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials. gov and published in journals. PLoS Med 2013;10:e1001566, discussion e1001566. doi:10. 1371/journal. pmed. 1001566
22. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Structure and Content of Clinical Study Reports [Internet]. 1995 [cited 2015 May 28]. Available from: http://www. ich. org/products/ guidelines/efficacy/efficacy-single/article/structure-and-content-ofclinical-study-reports. html
23. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med 2012;9:e1001201. doi:10. 1371/journal. pmed. 1001201
24. Wieseler B, Wolfram N, McGauran N. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Med 2013;10:e1001526. doi:10. 1371/journal. pmed. 1001526
25. Goldacre B. Bad pharma: how medicine is broken, and how we can fix it. Fourth Estate, 2013.
26. Sydes MR, Johnson AL, Meredith SK, Rauchenberger M, South A, Parmar MK. Sharing data from clinical trials: the rationale for a controlled access approach. Trials 2015;16:104. doi:10. 1186/ s13063-015-0604-6
27. Goldacre B. Commentary on Berlin et al "Bumps and bridges on the road to responsible sharing of clinical trial data. " Clin Trials Lond Engl 2014;11:15-8doi:10. 1177/1740774513515768.
28. Institute of Medicine. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Committee on Strategies for Responsible Sharing of Clinical Trial Data; Board on Health Sciences Policy. 2015, National Academies Press. Available from: https://www. ncbi. nlm. nih. gov/ books/NBK286002/
29. PMLiVE. Top 25 pharma companies by global sales [Internet]. 2014 [cited 2017 Jun 30]. Available from: http://www. pmlive. com/ top-pharma-list/global-revenues
30. International Committee of Medical Journal Editors. ICMJE Recommendations [Internet]. 2015 [cited 2016 Apr 27]. Available from: http://www. icmje. org/recommendations/browse/
31. DeAngelis CD, Drazen JM, Frizelle FAInternational Committee of Medical Journal Editors. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. JAMA 2005;293:2927-9. doi:10. 1001/jama. 293. 23. jed50037
32. Sim I, Chan A-W, Gülmezoglu AM, Evans T, Pang T. Clinical trial registration: transparency is the watchword. Lancet 2006;367: 1631-3. doi:10. 1016/S0140-6736(06)68708-4
33. World Health Organisation. WHO ICTRP [Internet]. WHO. [cited 2015 Aug 10]. Available from: http://www. who. int/ictrp/en/
34. Commissioner O of the Food and Drug Administration Amendments Act (FDAAA) of 2007 [Internet]. 2007 [cited 2016 Apr 27]. Available from: https://www. fda. gov/regulatoryinformation/ lawsenforcedbyfda/significantamendmentstothefdcact/ foodanddrugadministrationamendmentsactof2007/default. htm
35. Kmietowicz Z. Transparency campaigners welcome new rules for clinical trials in Europe. BMJ 2014;348:g2579. doi:10. 1136/bmj. g2579
36. Davis AL, Miller JD. The European Medicines Agency and Publication of Clinical Study Reports: A Challenge for the US FDA. JAMA 2017;317:905-6. http://jamanetwork. com/journals/jama/ fullarticle/2605437. doi:10. 1001/jama. 2017. 0918
37. AllTrials. The AllTrials Campaign [Internet]. 2013 [cited 2014 Jan 9]. Available from: http://www. alltrials. net/
38. Lo B. Sharing clinical trial data: maximizing benefits, minimizing risk. JAMA 2015;313:793-4. doi:10. 1001/jama. 2015. 292
39. Taichman DB, Backus J, Baethge C. Sharing Clinical Trial Data-A Proposal from the International Committee of Medical Journal Editors. N Engl J Med 2016;374:384-6. doi:10. 1056/NEJMe1515172
40. Policy Audit [Internet]. [cited 2017 Jun 28]. Available from: http://policyaudit. alltrials. net/
41. Powell-Smith A, Goldacre B. The TrialsTracker: Automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions. F1000Res 2016;5:2629. doi:10. 12688/f1000research. 10010. 1
42. Krumholz HM, Gross CP, Blount KL. Sea change in open science and data sharing: leadership by industry. Circ Cardiovasc Qual Outcomes 2014;7:499-504. doi:10. 1161/CIRCOUTCOMES. 114. 001166
43. Dwan K, Gamble C, Williamson PR, Altman DG. Reporting of clinical trials: a review of research funders' guidelines. Trials 2008;9:66. doi:10. 1186/1745-6215-9-66
44. United States Dept of Justice. Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-label Drug Marketing [Internet]. 2010 [cited 2010 Nov 23]. Available from: http://www. justice. gov/opa/pr/2010/ April/10-civ-487. html
45. United States Dept of Justice. Johnson & Johnson to Pay More Than $2. 2 Billion to Resolve Criminal and Civil Investigations [Internet]. 2013 [cited 2016 Sep 12]. Available from: https://www. justice. gov/ opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-andcivil-investigations
46. United States Dept of Justice. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data [Internet]. 2009 [cited 2016 Sep 12]. Available from: https://www. justice. gov/opa/pr/glaxosmithkline-plead-guilty-andpay-3-billion-resolve-fraud-allegations-and-failure-report
47. United States Dept of Justice. Justice Department Announces Largest Health Care Fraud Settlement in Its History [Internet]. 2009 [cited 2016 Sep 12]. Available from: https://www. justice. gov/opa/pr/ justice-department-announces-largest-health-care-fraud-settlementits-history